WAVE — Waverley Pharma Income Statement
0.000.00%
Last trade - 00:00- CA$0.54m
- CA$3.26m
- CA$0.41m
Annual income statement for Waverley Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.16 | 1.38 | 1.75 | 1.25 | 0.412 |
| Cost of Revenue | |||||
| Gross Profit | 0.049 | 0.182 | 0.223 | 0.284 | 0.08 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.57 | 2.08 | 2.54 | 2.18 | 2.64 |
| Operating Profit | -1.41 | -0.71 | -0.787 | -0.936 | -2.23 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.21 | -0.706 | -0.797 | -0.664 | -2.22 |
| Net Income After Taxes | -1.21 | -0.706 | -0.797 | -0.664 | -2.22 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.21 | -0.706 | -0.797 | -0.664 | -2.22 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.21 | -0.706 | -0.797 | -0.664 | -2.22 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.022 | -0.015 | -0.014 | -0.012 | -0.024 |